Zenapax (Hoffmann-La Roche Inc)
Zenapax (Hoffmann-La Roche Inc) Brand names, Zenapax (Hoffmann-La Roche Inc) Analogs
Zenapax (Hoffmann-La Roche Inc) Brand Names Mixture
- No information avaliable
Zenapax (Hoffmann-La Roche Inc) Chemical_Formula
C6332H9808N1678O1989S42
Zenapax (Hoffmann-La Roche Inc) RX_link
http://www.rxlist.com/cgi/generic3/zenapax.htm
Zenapax (Hoffmann-La Roche Inc) fda sheet
Zenapax (Hoffmann-La Roche Inc) msds (material safety sheet)
Zenapax (Hoffmann-La Roche Inc) Synthesis Reference
Sequence listed in humanized anti-Tac, PNAS 1989 with Queen, C, Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods. 2005 May;36(1):69-83.
Zenapax (Hoffmann-La Roche Inc) Molecular Weight
142612.1
Zenapax (Hoffmann-La Roche Inc) Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Zenapax (Hoffmann-La Roche Inc) H2O Solubility
No information avaliable
Zenapax (Hoffmann-La Roche Inc) State
Liquid
Zenapax (Hoffmann-La Roche Inc) LogP
-0.437
Zenapax (Hoffmann-La Roche Inc) Dosage Forms
Solution (IV)
Zenapax (Hoffmann-La Roche Inc) Indication
For prevention of renal transplant rejection
Zenapax (Hoffmann-La Roche Inc) Pharmacology
Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
Zenapax (Hoffmann-La Roche Inc) Absorption
No information avaliable
Zenapax (Hoffmann-La Roche Inc) side effects and Toxicity
No information avaliable
Zenapax (Hoffmann-La Roche Inc) Patient Information
No information avaliable
Zenapax (Hoffmann-La Roche Inc) Organisms Affected
Humans and other mammals
